XRP1 SILENCE THERAPEUTICS PLC

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

LONDON--(BUSINESS WIRE)--

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 10:00 a.m. ET.

The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. Silence also maintains research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit .

EN
26/11/2024

Underlying

XRP1SILENCE THERAPEUTICS PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SILENCE THERAPEUTICS PLC

 PRESS RELEASE
Free
XRP1 SILENCE THERAPE...

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia V...

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California. “Additional divesiran data presented at ASH continue to support a compelling profile in PV and highlight the broad potential of o...

December 9, 2024 1 EN
 PRESS RELEASE
Free
XRP1 SILENCE THERAPE...

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler ...

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 10:00 a.m. ET. The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference. About Silence Therapeuti...

November 26, 2024 1 EN
 PRESS RELEASE
Free
XRP1 SILENCE THERAPE...

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at...

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sess...

November 18, 2024 1 EN
 PRESS RELEASE
Free
XRP1 SILENCE THERAPE...

Silence Therapeutics Reports Third Quarter 2024 Financial Results and ...

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights. “The Silence team is focused on continued execution across the business,” said Craig Tooman, President and Chief Executive Officer at Silence. “We look forward to presenting additional data from our wholly owned clinical programs ...

November 14, 2024 1 EN
 PRESS RELEASE
Free
XRP1 SILENCE THERAPE...

Silence Therapeutics to Participate in Fireside Chat at the Jefferies ...

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20th at 2:00 p.m. GMT. The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silenc...

November 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch